The champagne corks are probably still rolling around at Cerapedics HQ. In June 2025, the company secured FDA premarket approval for its PearlMatrix™ P-15 Peptide Enhanced Bone Graft — and now they’ve marked another milestone: the first U.S. patient treated post-approval.
Biologics Premium
PearlMatrix™ Hits the OR: First U.S. Patient Post-FDA Approval
1 min read Premium comments

StudiesPremiumtransforaminal lumbar interbody fusionbone growth acceleratorPearlMatrix Bone GraftSharad Rajpal#cerapedics#tlif
React:
